Advertisment
Indian Journal of Nephrology About us |  Subscription |  e-Alerts  | Feedback | Login   
  Print this page Email this page   Small font sizeDefault font sizeIncrease font size
 Home | Current Issue | Archives| Ahead of print | Search |Instructions |  Editorial Board  

Users Online:1355

Official publication of the Indian Society of Nephrology
 ~   Next article
 ~   Previous article
 ~   Table of Contents

 ~   Similar in PUBMED
 ~  Search Pubmed for
 ~  Search in Google Scholar for
 ~Related articles
 ~   Citation Manager
 ~   Access Statistics
 ~   Reader Comments
 ~   Email Alert *
 ~   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1660    
    Printed144    
    Emailed0    
    PDF Downloaded179    
    Comments [Add]    

Recommend this journal

 

 CASE REPORT
Year : 2010  |  Volume : 20  |  Issue : 1  |  Page : 51-53

Mycophenolic acid area under the curve recovery time following rifampicin withdrawal


1 Department of Nephrology, Christian Medical College, Vellore, India
2 Department of Clinical Pharmacology, Christian Medical College, Vellore, India

Correspondence Address:
G T John
Senior Consultant, Department of Renal Medicine, Level 9, Ned Hanlon Building, Royal Brisbane and Women's Hospital, Herston QLD 4029, Australia

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0971-4065.62091

Rights and Permissions

Renal transplant patients prescribed mycophenolate mofetil (MMF) may require treatment for tuberculosis with a regimen including the tuberculocidal drug rifampicin. MMF is an ester prodrug which is rapidly hydrolysed to the active compound, mycophenolic acid (MPA). Therapeutic drug monitoring of mycophenolate involves the measurement of MPA area under the curve (MPA-AUC 0-12 ). Rifampicin is known to increase the metabolism and decrease enterohepatic recirculation of mycophenolic acid, (MPA). When MPA is monitored after the discontinuation of rifampicin, an important factor is the time required for the MPA area under the curve to return to the pre-rifampicin value. At present this is not known. This report describes one such renal allograft patient, on long term MMF and prescribed rifampicin by a local physician. As expected there was a clinically significant decrease in MPA-AUC 0-12 . Three weeks after rifampicin was discontinued the MPA-AUC 0-12 was still only 65% of the pre-rifampicin value and only 55% of the steady state MPA-AUC 0-12 measured six months later.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

Indian Journal of Nephrology
Published by Wolters Kluwer - Medknow
Online since 20th Sept '07